A new analysis of the one-year PARTNER 3 results show TAVR with Edwards Lifesciences Corp.’s Sapien 3 offers a modest disease-specific health status advantage over surgical valve replacement.
The one-year results from PARTNER 3, published in May, showed TAVR with Sapien 3 resulted in lower rates of...